4.7 Article

Myeloma Bone Disease: Recent Advances in Biology, Diagnosis, and Treatment

Journal

ONCOLOGIST
Volume 14, Issue 3, Pages 276-283

Publisher

WILEY
DOI: 10.1634/theoncologist.2009-0003

Keywords

Multiple myeloma; Bone; Biochemical markers; Osteoclast; Osteoblast; RANKL; Osteoprotegerin; MIP-1; DKK-1; ICTP

Categories

Ask authors/readers for more resources

Bone disease is a hallmark of multiple myeloma (MM). Occurring in the majority of MM patients, it is associated with bone pain, fractures, and hypercalcemia and has major impacts on quality of life. Furthermore, bone resorption activity has been shown to be an independent risk factor for overall survival in patients with symptomatic MM. Myeloma is characterized by a unique form of bone disease with lytic bone destruction that is not followed by reactive bone formation (uncoupling). This review focuses on recent advances in our understanding of the biology of osteoclast activation and osteoblast inhibition in MM, diagnostic standards, and recent progress in treatment options for myeloma bone disease. Translational research has enabled a rapid transfer of mechanistic insights from the bench to the bedside and will hopefully result in better treatment options and outcome for patients in near future. The Oncologist 2009; 14: 276-283

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available